Post-earnings recap
Reported
Thu, Feb 27, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.09% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's short-term outlook. The management's focus on clinical trials suggests they are prioritizing long-term growth over immediate financial performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.64 | N/A | -6.51% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance without providing specific guidance. They emphasized their commitment to advancing clinical programs.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on its ongoing clinical trials and product development.